Close Menu

NEW YORK – The UK's National Institute for Health and Care Excellence published a final draft guidance on Tuesday recommending venetoclax (AbbVie's Venclyxto) plus obinutuzumab (Roche's Gazyva) without chemotherapy for untreated chronic lymphocytic leukemia (CLL) patients with certain genetic mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.